A Combination of Fludarabine/Rituximab with Escalating Doses of Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL): The REVLIRIT CLL5 AGMT Phase I/II Study, Clinical and Exploratory Analyses of Induction Results

被引：5

作者：

Egle, Alexander ^{[1
]}

Steurer, Michael ^{[2
]}

Gassner, Franz ^{[1
]}

Geisberger, Roland ^{[1
]}

Melchardt, Thomas ^{[1
]}

Weiss, Lukas ^{[1
]}

Fridrik, Michael A. ^{[3
]}

Thaler, Josef ^{[4
]}

Lang, Alois ^{[5
]}

Greil, Richard ^{[1
]}

机构：

[1] Univ Hosp Salzburg, Dept Med 3, Lab Immunol & Mol Canc Res, Salzburg, Austria

[2] Innsbruck Med Univ, Div Hematol & Oncol, Lab Mol Genet & Diagnost, Innsbruck, Austria

[3] Gen Hosp Linz GesmbH, Ctr Hematol & Med Oncol, Linz, Austria

[4] Hosp Wels Grieskirchen, Dep Internal Med 4, Wels, Austria

[5] Hosp Feldkirch, Feldkirch, Austria

来源：

关键词：

D O I：

10.1182/blood.V118.21.292.292

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：135 / 136

页数：2